TVM Capital led a hefty $35.2 million third round of venture capital for Colorado's Argos Therapeutics. The funding will be used to support Argos' Phase II trial of Arcelis immunotherapy drug candidates in renal cell carcinoma and HIV. In addition, it will finance the company's CD83 protein immunology program through an initial human clinical trial in transplantation.
"We believe that the Company's many near-term data events, combined with its ability to move into additional cancer and infectious disease indications with its Arcelis platform technology, as well autoimmune disorders with its CD83 soluble protein, position Argos as a leader in the immunotherapy field,"Â said Hubert Birner, Ph.D., General Partner of TVM Capital and Argos' Chairman.Â Argos was featuredÂ in FierceBiotech's weekly column on emerging drug developers.Â
- see this Argos release
Argos, J&J make a deal
Argos, Therakos ink deal
In VC market, life sciences dominate